Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Short term Debt (2018 - 2024)

Orthofix Medical has reported Short term Debt over the past 10 years, most recently at $7.1 million for Q4 2024.

  • For the quarter ending Q4 2024, Short term Debt rose 468.0% year-over-year to $7.1 million, compared with a TTM value of $7.1 million through Dec 2024, up 468.0%, and an annual FY2024 reading of $7.1 million, up 468.0% over the prior year.
  • Short term Debt came in at $7.1 million for Q4 2024, up from $6.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $17.2 million in Q4 2021 to a low of $1.0 million in Q4 2022.
  • Median Short term Debt over the past 5 years was $5.5 million (2024), compared with a mean of $6.9 million.
  • The sharpest move saw Short term Debt crashed 94.19% in 2022, then surged 468.0% in 2024.
  • Over 5 years, Short term Debt stood at $14.9 million in 2020, then grew by 15.44% to $17.2 million in 2021, then crashed by 94.19% to $1.0 million in 2022, then rose by 25.0% to $1.2 million in 2023, then surged by 468.0% to $7.1 million in 2024.
  • Per Business Quant, the three most recent readings for OFIX's Short term Debt are $7.1 million (Q4 2024), $6.2 million (Q3 2024), and $4.7 million (Q2 2024).